Propanedioic acid, monoethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Propanedioic acid, monoethyl ester
• 英文别名: 3-ethoxy-3-oxopropanoate
• 化学式: C5H7O4-
• 分子量: 131.11
• InChiKey: HGINADPHJQTSKN-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  66.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-甲氧基-3-吡啶甲醛 、 Propanedioic acid, monoethyl ester 在 哌啶 乙醚 、 氨 、 水 作用下， 以 吡啶 为溶剂， 反应 5.0h， 以to give ethyl 3-(6-methoxy-3-pyridyl)acrylate (2.8 g, 79%) m.p. 49°-52°的产率得到ethyl (6-methoxypyridin-3-yl)acrylate
  参考文献：
  名称：

  Pyrimidine compounds

  摘要：

  这些化合物是替代嘧啶化合物，是组胺H.sub.2-拮抗剂。本发明的一种特定化合物是2-[2-(5-二甲氨基甲基)-2-呋喃甲硫基)乙基氨基]-5-(3-吡啶甲基)-4-嘧啶酮。

  公开号：

  US04539207A1
• 作为试剂：
  描述：

  Propanedioic acid, monoethyl ester 、 Magnesium ethoxide 、 2,6-二氯烟酸 、 、 、 乙酸乙酯 在 ice 、 magnesium salt 、 Propanedioic acid, monoethyl ester 、 柠檬酸 、 sodium hydrogen carbonate water 、 solution 、 Sodium sulfate-III 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 8.67h， 以4.24 g (81%) of the title compound was obtained in the form of a pale-pink, oily substance from an n-hexane的产率得到3-(2,6-二氯吡啶-3-基)-3-氧代丙酸乙酯
  参考文献：
  名称：

  Dehalogeno-compounds

  摘要：

  具有特定取代基的3-(1-氨基环烷基)吡咯烷基取代的6-去卤代(氢取代)喹诺酮羧酸衍生物，其盐和水合物，如下式(I)所示，表现出广谱和强效的抗菌活性，对革兰氏阴性菌和革兰氏阳性菌，特别是以革兰氏阳性球菌为代表的耐药菌，包括MRSA、PRSP和VRE均有效。因此，这些化合物可用作药物。

  公开号：

  US07902226B2

文献信息

• 4-(M-benzoylphenyl)butyric acid derivatives
  申请人：Roussel-UCLAF

  公开号：US03931302A1

  公开（公告）日：1976-01-06

  Novel butyric acid derivatives of the formula ##SPC1## Wherein X, X.sub.1, X.sub.2 and X.sub.3 are individually selected from the group consisting of hydrogen, halogen, lower alkyl of 1 to 5 carbon atoms, lower alkoxy of 1 to 5 carbon atoms, lower alkylthio of 1 to 5 carbon atoms, trifluoromethoxy, trifluoromethylthio, trifluoromethyl, OH and dilower alkylamino of 1 to 5 carbon atoms for each alkyl, R is selected from the group consisting of hydrogen, lower alkyl of 1 to 5 carbon atoms, o-carboxyphenyl, 2,3-dihydroxypropyl and -CH.sub.2 -CH - CH.sub.2 ##EQU1## wherein P and Q are individually lower alkyl of 1 to 5 carbon atoms, Z and X.sub.4 are individually selected from the group consisting of hydrogen and lower alkyl of 1 to 5 carbon atoms and Y is selected from the group consisting of hydrogen and --OH and the dotted line indicates the optional presence of a double bond when Y is hydrogen and when R is hydrogen or o-carboxyphenyl, the salts thereof with a non-toxic pharmaceutically acceptable mineral or organic base, which compounds have anti-inflammatory and analgesic activity and are substantially devoid of ulcerigenic activity and their preparation and novel intermediates formed therein.

  化合物的式子为##SPC1##，其中X、X.sub.1、X.sub.2和X.sub.3分别选自氢、卤素、1-5个碳原子的低级烷基、1-5个碳原子的低级烷氧基、1-5个碳原子的低级烷基硫基、三氟甲氧基、三氟甲基硫基、三氟甲基、羟基和每个烷基的1-5个碳原子的双低级烷基氨基；R选自氢、1-5个碳原子的低级烷基、o-羧基苯基、2,3-二羟基丙基和-CH.sub.2-CH-CH.sub.2 ##EQU1##其中P和Q分别为1-5个碳原子的低级烷基，Z和X.sub.4分别选自氢和1-5个碳原子的低级烷基，Y选自氢和-OH，虚线表示当Y为氢时，R为氢或o-羧基苯基时，存在一个可选的双键。该化合物与非毒性药用可接受的矿物质或有机碱的盐具有抗炎和镇痛活性，并且基本上没有溃疡原性活性。该化合物的制备以及在其中形成的新中间体。
• Azole compounds
  申请人：Sakai Nozomu

  公开号：US20050090534A1

  公开（公告）日：2005-04-28

  The present invention provides a compound represented by the formula (I) wherein R 1 is a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group, A is an optionally substituted cyclic amino group or —NR 2 —W-D wherein R 2 is a hydrogen atom or an alkyl group, W is a bond or a divalent acyclic hydrocarbon group, and D is an optionally substituted cyclic group, an optionally substituted amino group or an optionally substituted acyl group, B is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom, and Y is a bond or a divalent acyclic hydrocarbon group, or a salt thereof, which is useful for the prophylaxis or treatment of diabetic neuropathy and the like.

  本发明提供了一种化合物，其表示为公式(I)，其中R1是氢原子、卤素原子、可选取代的碳氢基团、可选取代的杂环基团、可选取代的羟基、可选取代的硫醇基或可选取代的氨基；A是可选取代的环状氨基基团或-NR2-W-D，其中R2是氢原子或烷基团，W是键或双价的无环烃基团，D是可选取代的环状基团、可选取代的氨基或可选取代的酰基团；B是可选取代的碳氢基团或可选取代的杂环基团；X是氧原子、硫原子或可选取代的氮原子；Y是键或双价的无环烃基团，或其盐。该化合物对于预防或治疗糖尿病性神经病等方面有用。
• Beta-ketoamide compounds with MCH antagonistic activity
  申请人：Roth Juergen Gerald

  公开号：US20050245500A1

  公开（公告）日：2005-11-03

  Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R 1 , R 2 , R 3 , R 5a and R 5b have the meanings given in claim 1 . The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

  公式I的化合物，其中A、B、b、X、Y、Z、R1、R2、R3、R5a和R5b的基团和残基具有权利要求1中给出的含义。本发明还涉及含有至少一种根据本发明的酰胺的制药组合物。由于其MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• Solar cells incorporating light harvesting arrays
  申请人：——

  公开号：US20020185173A1

  公开（公告）日：2002-12-12

  A solar cell incorporates a light harvesting array that comprises: (a) a first substrate comprising a first electrode; and (b) a layer of light harvesting rods electrically coupled to the first electrode, each of the light harvesting rods comprising a polymer of Formula I: 1 X 1 ⁢ — ( X m + 1 ) m ( I ) wherein m is at least 1, and may be from two, three or four to 20 or more; X 1 is a charge separation group (and preferably a porphyrinic macrocycle, which may be one ligand of a double-decker sandwich compound) having an excited-state of energy equal to or lower than that of X 2 ; and X 2 through X m+1 are chromophores (and again are preferably porphyrinic macrocycles).

  太阳能电池包括一个光收集阵列，其中包括：(a) 第一基底，包括第一电极；和 (b) 与第一电极电耦合的光收集棒层，其中每个光收集棒包括式I的聚合物：1X1⁢—(Xm+1)m(I)，其中m至少为1，可以是从2、3或4到20或更多；X1是一个电荷分离基团（最好是卟啉大环，可以是双层夹心化合物的一个配体）具有与X2相等或更低的激发态能量；而X2到Xm+1是色团（同样最好是卟啉大环）。
• Pyridinyl-quinolone compounds, their preparation and use
  申请人：Sterling Drug Inc.

  公开号：US05169853A1

  公开（公告）日：1992-12-08

  Fluorinated 1- cyclopropyl-7-(substituted-pyridinyl)-1,4-dihydro-4-oxo-3-quinolinecarboxy lic acids of the formula ##STR1## wherein R is hydrogen, R' and R" are hydrogen or fluoro, and Z is 3- or 4-pyridinyl substituted by alkyl groups or substituted alkyl groups, are superior antibacterial agents. They are prepared via a coupling reaction between the corresponding esters (R=alkyl) having a halo group in the 7-position and a substituted (trialkylstannyl)-pyridine.

  化合物的中文翻译如下：氟代1-环丙基-7-(取代吡啶基)-1,4-二氢-4-氧代-3-喹啉羧酸，其化学式为##STR1##其中R为氢，R'和R"为氢或氟，Z为被烷基或取代烷基取代的3-或4-吡啶基。它们是优良的抗菌剂。它们通过对应酯（R=烷基）在7位具有卤素基和取代（三烷基锡基）-吡啶之间的偶联反应制备而成。